Public Release: 

New 3-D human skin models could replace animal testing to assess dermal sensitivity to medical device

Mary Ann Liebert, Inc./Genetic Engineering News

IMAGE

IMAGE: Applied In Vitro Toxicology is a new peer-reviewed journal providing the latest research on the application of alternative in vitro testing methods for predicting adverse effects in the pharmaceutical, chemical,... view more

Credit: ©Mary Ann Liebert, Inc., publishers

New Rochelle, NY, July 29, 2015--New research shows that exposing a 3D human skin tissue model to extracts of medical device materials can detect the presence of sensitizers known to cause an allergic response on contact in some individuals. Conventional skin sensitization testing of medical devices relies on animal testing, whereas human skin models could replace animal methods, according to an article in the new journal Applied In Vitro Toxicology, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The article is available free on the Applied In Vitro Toxicology website until August 29, 2015.

Kelly Coleman, Lori McNamara, Thomas Grailer, Medtronic PLC (Minneapolis, MN), Jamin Willoughby, Donald Keller, Cyprotex US LLC (Kalamazoo, MI), and Prakash Patel, Simon Thomas, and Clive Dilworth, Cyprotex PLC (Macclesfield, UK), describe experiments using EpiDerm™, a reconstructed human epidermal tissue model, and the SenCeeTox® assay, which monitors survival of the skin cells, their reactivity, and changes in the expression of specific genes on exposure to chemicals that may cause a hypersensitivity reaction.

In the article "Evaluation of an In Vitro Human Dermal Sensitization Test for Use with Medical Device Extracts", the researchers show that this method was able to detect the presence of known skin sensitizers in medical device extracts, even if the sensitizers are present at very low levels.

About the Journal

Applied In Vitro Toxicology is a new peer-reviewed journal providing the latest research on the application of alternative in vitro testing methods for predicting adverse effects in the pharmaceutical, chemical, and personal care industries. Led by Editor-in-Chief James M. McKim, PhD, DABT, Founder and CEO, IONTOX, LLC, the Journal addresses important issues facing these diverse industries, including regulatory requirements; the reduction, refinement, and replacement of animal testing; new screening methods; evaluation of new cell and tissue models; and the most appropriate methods for assessing safety and satisfying regulatory demands. The Journal is published quarterly online with Open Access options and in print. A sample issue may be viewed on the Applied In Vitro Toxicology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including ASSAY and Drug Development Technologies, Human Gene Therapy, and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.